Table 3

Standardised incidence ratios (SIRs) and 95% CIs) in US systemic lupus erythematosus renal transplant recipients compared to the US general population stratified by race/ethnicity

Cancer typeObserved cases*Expected cases*Overall SIR (95% CI)White SIR (95% CI)Non-white SIR (95% CI)Hispanic SIR (95% CI)Non-Hispanic SIR (95% CI)
All cancers16224663.7 (2.1 to 5.7)4.5 (1.9 to 7.0)3.6 (2.1 to 5.1)3.6 (1.7 to 5.6)4.0 (2.1 to 5.8)
Lip/oropharyngeal7911172. (57.3 to 92.0)58.8 (28.9 to 89.1)69.9 (42.3 to 97.3)69.4 (16.6 to 122.1)59.9 (31.5 to 88.4)
Kaposi38138 (35.2 to 141.1)11.8 (5.0 to 39.7)42.3 (12.1 to 97.5)0134.3 (10.0 to 278.0)
Neuroendocrine†163532.6 (30.7 to 50.2)23.5 (6.9 to 40.1)36.8 (9.2 to 64.4)24.8 (21.0 to 39.5)23.0 (11.3 to 58.2)
Thyroid2831028.3 (16.2 to 41.2)25.5 (7.5 to 43.4)51.0 (31.8 to 70.0)31.7 (6.4 to 57.0)26.5 (14.6 to 38.5)
Renal2171415.5 (12.3 to 21.7)14.7 (9.7 to 19.6)18.7 (8.6 to 28.7)7.4 (1.0 to 14.3)16.3 (9.8 to 22.8)
Cervical133816.65 (3.0 to 27.3)14.3 (7.2 to 21.1)19.0 (9.7 to 28.2)4.6 (–)‡23.3 (0.7 to 45.7)
Lymphoma2932213.3 (9.0 to 14.6)12.3 (8.0 to 16.5)16.8 (8.9 to 24.7)19.1 (4.9 to 33.3)13.8 (6.6 to 21.1)
Liver4066.64 (5.5 to 7.3)NANANANA
Colorectal222494.5 (3.2 to 6.1)4.8 (2.5 to 7.1)3.3 (1.1 to 5.6)6.4 (1.6 to 14.5)5.1 (3.1 to 7.1)
Ovarian32132.4 (1.3 to 5.6)1.4 (1.4 to 1.5)2.3 (2.2 to 2.4)00.8‡ (–)
Melanoma27201.4 (1.6 to 2.8)1.8 (0.0 to 3.5)19.9 (0.0 to 35.3)01.6 (0.7 to 2.5)
Breast2551272.0 (1.1 to 3.1)1.7 (0.8 to 2.6)3.1 (1.8 to 4.4)5.0 (1.2 to 8.8)2.1 (1.2 to 3.1)
Lung43650.7 (0.6 to 1.0)0.8 (0.3 to 1.3)0.4 (0.2 to 0.7)00.9 (0.6 to 1.1)
Prostate541630.33 (0.01 to 1.0)0.1 (0.1 to 0.3)0.5 (0.0 to 1.0)0.9 (0.5 to 3.1)0.4 (0.1 to 0.6)
  • *Observed and expected cases reported per 100 000 person-years. †Neuroendocrine tumours included carcinoid, islet cell, medullary thyroid and pheochromocytoma. ‡Only one case=not available due to small number of cases. NA, not available due to small number of cases.